Bryan Giraudo Bought 21% More Shares In Gossamer Bio
Bryan Giraudo Bought 21% More Shares In Gossamer Bio
Even if it's not a huge purchase, we think it was good to see that Bryan Giraudo, the COO & CFO of Gossamer Bio, Inc. (NASDAQ:GOSS) recently shelled out US$59k to buy stock, at US$0.59 per share. That purchase might not be huge but it did increase their holding by 21%.
即使這不是一筆巨額購買,我們認爲看到Gossamer Bio,Inc. (納斯達克:GOSS)的COO&CFO Bryan Giraudo最近以每股0.59美元的價格購買了價值59,000美元的股票是一個好信號。雖然這次購買可能不是很大,但他們的持股比例增長了21%。
Gossamer Bio Insider Transactions Over The Last Year
在過去一年中,Gossamer Bio公司內部交易情況
Notably, that recent purchase by COO & CFO Bryan Giraudo was not the only time they bought Gossamer Bio shares this year. They previously made an even bigger purchase of US$113k worth of shares at a price of US$0.56 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$0.65. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
值得注意的是,COO&CFO Bryan Giraudo今年購買Gossamer Bio股票的次數不止一次。他們之前花了113,000美元以每股0.56美元的價格購買了更多的股票。雖然我們喜歡看到內部人員購買股票,但我們注意到,這次巨額購買的價格遠低於最近的0.65美元的股價。雖然這表明內部人員認爲股票被低估但價格較低,但這次交易並不能告訴我們他們對當前股價的看法。
In the last twelve months insiders purchased 357.00k shares for US$212k. But they sold 44.07k shares for US$52k. In the last twelve months there was more buying than selling by Gossamer Bio insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去的十二個月中,內部人員以212,000美元購買了357,000股股票。但他們賣出了44,070股股票,售價爲52,000美元。在過去的十二個月中,Gossamer Bio內部人員購買的比賣出的要多。您可以在下面查看內部交易的視覺描述(公司和個人)。如果單擊圖表,便可以查看所有的個人交易,包括股價、個人和日期!
![insider-trading-volume](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240623/0-33b3a3aabf0fd24d2c9353c92ce80a12-0-352e169d4247cd8b5de88c28e437a3d8.png/big)
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
內部人士正在購買的股票是無數的。如果您喜歡投資於較少知名公司,您可以查看此免費的公司列表(提示:內部人士一直在購買它們)。
Insider Ownership
內部人員持股情況
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From looking at our data, insiders own US$4.3m worth of Gossamer Bio stock, about 3.0% of the company. I generally like to see higher levels of ownership.
另一種測試公司領導與其他股東之間的協調程度的方法是查看他們擁有多少股份。一般情況下,內部人員持股比例越高,他們就越可能受到激勵,爲長期建設公司貢獻力量。從我們的數據來看,內部人員持有價值4.3百萬美元的Gossamer Bio股票,約佔公司總市值的3.0%。我通常希望看到更高水平的持股比例。
So What Does This Data Suggest About Gossamer Bio Insiders?
關於Gossamer Bio內部人員,這些數據意味着什麼?
Our data shows a little insider buying, but no selling, in the last three months. Overall the buying isn't worth writing home about. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if Gossamer Bio insiders bought more shares in the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 4 warning signs for Gossamer Bio (2 are a bit unpleasant!) and we strongly recommend you look at these before investing.
我們的數據顯示,在過去的三個月中,內部人員有少量購買行爲,但沒有賣出行爲。整體而言,購買行爲並沒有太大價值。但在過去一年中,內部人員對該股表現出更多的興趣。雖然了解內部人員的所有權和交易情況很重要,但在做出任何投資決策之前,我們還要確定股票面臨哪些風險。我們的分析顯示Gossamer Bio(其中有2個不太令人愉快的)存在4個警示信號,強烈建議您在投資之前閱讀。
Of course Gossamer Bio may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Gossamer Bio可能不是最好的股票選擇。因此,您可能希望查看這些高質量公司的免費收藏。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。